Table 2.
Regimen-related toxicities
| Complications | Standard dose busulfan group (n = 25) | Lower dose busulfan group (n = 20) | P |
|---|---|---|---|
| Oral mucositis (≥grade 3) | 21 | 11 | .048 |
| Hyperbilirubinemia (≥grade 3) | 9 | 3 | .019 |
| Hypertension (≥grade 3) | 8 | 3 | .025 |
| Sinusoidal obstruction syndrome (SOS) | 1 | 0 | 1 |
| Infections (number of patients) | 17 | 15 | .10 |
| Bacterial | 4 | 4 | |
| Viral | 12 | 7 | |
| CMV (viremia/disease) | 5 (5/0) | 2 (2/0) | |
| EBV (viremia/disease) | 1 (1/0) | 1 (0/1) | |
| Adenovirus (viremia/disease) | 2 (0/2) | 1 (0/1) | |
| BK (viremia/disease) | 3 (1/2) | 0 | |
| HHV-6 (viremia/disease) | 0 | 1 (0/1) | |
| HSV (viremia/disease) | 0 | 1 (0/1) | |
| Influenza virus | 0 | 1 (0/1) | |
| RSV | 1 (0/1) | ||
| Fungal | 2 | 3 |
EBV, Epstein-Barr virus; HHV 6, human herpesvirus 6; HSV, herpes simplex virus; RSV, respiratory syncytial virus.